期刊文献+

重组人血管内皮抑素联合放化疗治疗非小细胞肺癌脑转移 被引量:6

暂未订购
导出
摘要 目的:观察重组人血管内皮抑素(恩度)联合多西他赛加顺铂方案及全脑放疗,治疗非小细胞肺癌脑转移患者的临床疗效.方法:45例非小细胞肺癌脑转移患者按治疗方案不同分为研究组24例和对照组21例,所有患者均接受DT=36~40 Gy的全脑普通放射治疗,在放疗同时应用多西他赛加顺铂方案化疗.研究组于放疗之前5d开始应用恩度,连用14d,休息7d为1个周期,连用2个周期;对照组仅接受多西他赛加顺铂和全脑放疗.观察两组的近期有效率、局部控制率、中位无进展生存时间以及中位生存时间.结果:研究组和对照组的近期有效率分别为79.2% (19/24)、66.7%(14/21),局部控制率分别为95.8% (23/24)、85.7%(18/21),差异均无统计学意义(P>0.05).研究组和对照组的中位无进展生存时间分别为12个月、8个月,两组中位生存时间分别为14个月、12个月,差异均具有统计学意义(P<0.05).结论:恩度联合多两他赛加顺铂方案及全脑放疗治疗非小细胞肺癌脑转移同单纯放化疗相比,不能提高有效率和局控率,但可延长无进展生存时间和总生存时间.
出处 《河南医学研究》 CAS 2014年第1期51-53,共3页 Henan Medical Research
  • 相关文献

参考文献13

  • 1Sheehan J P, Sun M H, Kondziolka D, et al. Radiosurgery for non- small cell lung carcinoma metastasis to the brain:Long-term outcomes and prognostic factors influencing patient survival time and local tumor control [ J ]. Neurosurg, 2002,97 ( 6 ) : 1276-1281.
  • 2Mujoomdar A, Austin J H, Malhotra R, et al. Clinical predictors of metastatic disease to the brain rom non-small cell lung carcinoma : Pri- mary tumorsize, cell type, and lymph node metastases[ J]. Radiolo- gy,2007,242 ( 3 ) :882-888.
  • 3罗文广,钱立庭,程广源.171例肺癌脑转移的治疗与预后[J].临床肺科杂志,2010,15(2):163-165. 被引量:17
  • 4Zimm S, Wampler G L, Stablein D, et al. Intracerebral metastases in solid-tunor patients: Naturalhistory and results of treatment [ J ]. Cancer,1981,48(2) : 384-394.
  • 5Eroglu G, Orb-an O, Unal D, et al. Concomitant ehemoradiotherapy with doeetaxel and cisplatin followed by consolidation chemotherapy in locally advanced unreseetable non-small cell lung cancer [ J ]. Ann Thorac Med, 2013,8 ( 2 ) : 109-115.
  • 6Sen F, Saglara E K, Toker A, et al. Weekly docetaxel and eisplatin with concomitant radiotherapy in addition to surgery and/or consolida- tion chemotherapy in stage Ⅲ non-small cell lung cancer[ J]. Cancer Chemother Pharmaeol, 2011,68 ( 6 ) : 1497-1505.
  • 7Li B, Wu X Y, Zhou H, et al. Acid-induced unfolding mechanismof recombinant human endostatin [ J ]. Biochemistry,2004,43 (9) :2550- 2557.
  • 8Ling Y,Yang Y,Lu N, et al. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/FIk-1 of endothelial cells[ J]. Bio- chem Biophys Res Commun, 2007,361 (1) :79-84.
  • 9Itasaka S, Komaki R, Herbst R S, et al. Endostatin improves radio- response and blocks tumor revascularization after radiation therapy for A431 xenografts in mice[ J]. International Journal of Radiation On- cology Biology Physics ,2007,67 (3) :870-878.
  • 10Winkler F, Kozin S V, Tong R T, et al. Kinetics of vascular normali- zation by VEGFR2 blockade governs brain tumor response to radia- tion: Role of oxygenation, angiopoietin-1, and matrix metalloprotein- ases[ J] , Cancer Cell,2004,6 (6) :553-563.

二级参考文献10

  • 1邱幸生,陈龙华,陈永清.87例非小细胞肺癌脑转移三维适形放疗疗效分析[J].中国肿瘤临床,2005,32(18):1025-1027. 被引量:4
  • 2Mujoomdar A, Austin JH, Malhotra R, et al. Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology,2007,242 ( 3 ) : 882 - 888.
  • 3Bindal AK, Bindal RK, Hess KR, et al. Surgery versus radiosurgery in the treatment of brain metastasis. J Neurosurg, 1996,84 (5) : 748.
  • 4Noel G,Medioni J, Valery CA,et al. Three irradiation treatment options including radiosurgery for brain metastases from primary lung cancer. Lung Cancer,2003,41 (3) :333 - 343.
  • 5Sheehan Jp Sun MH, Kondzioolka D, et al. Radiosurgery for non- small cell lung carcinoma metastatic to the brain:longterm outcomes and prognostic factors influencing patient survival time and local tumor control. J Neurosurg,2002,97 ( 6 ) : 1276 - 1281.
  • 6Furuse K, Kamimofi T, Kawahara M, et al. A pilot study of concurrent whole-brain radiotherapy and chemotherapy combined with cisplatin, vindesine and mitomycin in non-small-cell lung cancer with brain metastasis. Br J Cancer, 1997,75 (4) :614 - 618.
  • 7Fossell FV,Lee JS,MurPhy WK,et al. Phase Ⅱ study of docetaxel for recurrent or metastatic non-small-cell lung cancer [ J ]. J Clin Oncol, 1994,12 ( 6 ): 1238 - 1244.
  • 8Hainsworth JD, Greco FA. Phase Ⅰ trial of weekly docetaxel in patients with advancacd, refractory cancer [ J ]. Breast Cancer Res Treat, 1997,46 (59) :234-238.
  • 9Luck HJ,Donne S,Glaubitz M,et al. Phase Ⅰ study of weekly docetaxel in heavily pretreated breast cancer patients [ J ]. Eur J Cancer, 1997,33 ( suppl 8 ): 158-162.
  • 10杨焕军,张福林,蒋国梁,付小龙,钱浩,王丽娟.非小细胞肺癌脑转移放射剂量临床Ⅰ和Ⅱ期研究[J].中华放射肿瘤学杂志,2003,12(4):223-227. 被引量:9

共引文献40

同被引文献56

  • 1王金万,孙燕,刘永煜,于起涛,张沂平,李凯,朱允中,周清华,侯梅,管忠震,李维廉,庄武,王东林,梁后杰,秦凤展,卢辉山,刘晓晴,孙红,张燕军,王杰军,罗素霞,杨瑞合,涂远荣,王秀问,宋恕平,周静敏,游丽芬,王竞,姚晨.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290. 被引量:630
  • 2Jenny McGreevy,Ylva Orrevall,Kerstin Belqaid,Wendy Wismer,Carol Tishelman,Britt-Marie Bernhardson.Characteristics of taste and smell alterations reported by patients after starting treatment for lung cancer[J].Supportive Care in Cancer,2014,22(10):2635-2644.
  • 3Siegel R,Ma J,Zou Z,et al.Cancer statistics, 2014[J].CA (dancer J Clin,2014,64(1):9-29.
  • 4Eisenkop SM,Spirtos NM,Friedman RL,et al. Relative influences oftumor volume before surgery and the cytoredurtive out(;ome on survivalfor patients with advanced ovarian canrer : a prospec'tive study [j ].Gynecol Oncol, 2003,90 (2) :390-396.
  • 5Ozols RF,Bundy BN,Greer BE,et al.Phase III trial of carlioplatinand paclitaxel compared with cisplatin and paclitaxel in patients withoptimally resected stage III ovarian cancer: a Gynecologic OncologyGroup study[j].j Clin Oncol, 2003 ,21(17):3194-3200.
  • 6Ferrandina G,Ludovisi M,Lomsso D,et al.Phase trial of gemc-itabine compared with pegylated liposomal doxorubicin in progressiveor recurrent ovarian oancer[ J ].J Clin Oncol, 2008,26( 6) : 890-896.
  • 7Piccart-Gebhart GJ,Lacave A.A randomized phase II study of taxolor oxaliplatin in platinum-pretreated epithelial ovarian cancer (EOC)patients (pts) (abstract 1347) [j].Proc Am Soc Clin Oncol, 1998,17:349a.
  • 8Bookman MA.Gemcitabine monotherapy in recurrent ovarian cancer:from the bench to the clinic [j ].Int J Gynecol Cancer, 2005,15 (Sup-pl 1):12-17.
  • 9Raymond E’Faivre S,Chaney S,et al.Cellular and molecular phar-macology of oxaliplatin[j].Mol Cancer Ther,2002, 1(3):227-235.
  • 10Chollet P,Bensmaine MA,Brienza S,et al.Single agent activity ofoxaliplatin in heavily pretreated advanced epithelial ovarian cancer[j].Ann Oncol ,1996,7(10):1065-1070.

引证文献6

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部